The results of the affiliated Ruijin Hospital and Renji Hospital teams were published in the journals The Lancet and Nature, and the first clinical study for Chinese was published

Shanghai Jiao Tong University School of Medicine has always insisted on writing scientific research at the forefront of world science and technology, writing scientific research papers on the chapter of people's health, and constantly exploring more efficient treatment methods to help patients benefit
.

Explain the importance of protecting the elderly population during the COVID-19 pandemic

The Lancet published the blockbuster results of the affiliated Ruijin Hospital

Recently, Professor Wang Weiqing, Department of Endocrinology and Metabolism, Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine, Shanghai Institute of Endocrine and Metabolic Diseases, and National Clinical Research Center for Metabolic Diseases led a team to publish a corresponding article in The Lancet: "Protecting older people: a high priority during the COVID-19 pandemic"
.

Recently, the COVID-19 Omichron epidemic has affected many parts of China
.

At present, the aging of the population has become a worldwide problem, and the results of the 2021 census in China suggest that this problem is more serious
in China.

Based on this, the research team first took China's traditional culture and the characteristics of early COVID-19 epidemic prevention and control as the starting point, and combined with the survey data of Shanghai MMC, focused on analyzing the potential reasons for
the relatively low vaccination rate of the elderly population in the early stage.

On this basis, feasible strategies and considerations for protecting the elderly population are further proposed:

How to alleviate public concerns and promote vaccination among the elderly; How to combine hospital-based chronic disease management centers such as MMC with long-term care services to provide better chronic disease management and continuous care for the elderly; How to accelerate vaccine development for new variants and streamline the clinical approval process to address rapid COVID-19 variation; And for the elderly with contraindications to vaccination, how to find other ways to establish a protective barrier, etc
.

Therefore, through comprehensive thinking on the protection of the elderly population during the epidemic, this article provides a Chinese perspective for the global response to the new crown epidemic and provides a reference strategy
for comprehensively achieving healthy aging during the epidemic.

For the first time, a new pan-genomic research method has been used for human tumor genome research

The sub-journal Nature publishes the latest research results of Ruijin Hospital

Recently, Yu Yingyan, Zhu Zhenggang and others of Ruijin Hospital affiliated to Shanghai Jiao Tong University School of Medicine published research results entitled "Pangenomic analysis of Chinese gastric cancer" (doi: 10.

The Human Reference Genome "Sketch" released in 2001 is a major research result of the International Human Genome Project, which has greatly promoted the study
of disease genome and cancer genome.

In this study, HUPAN was used to analyze the whole genome depth sequencing data of 185 pairs of gastric cancer and paracancerous tissues (a total of 370 samples), and a gastric cancer pan-genome containing a new sequence of human reference genome (GRCh38) and 80.

For those new genes predicted by sequences other than the human reference genome, the research team used the long-read long sequences of the three-generation sequencing to conduct chromosomal localization research, and successfully localized the new gene GC0643 to the 9q34.

The use of cell line model in vitro overexpression of GC0643 gene significantly inhibits tumor cell growth, migration invasion, cell cycle progression and promotes apoptosis, and this tumor suppressor effect can be reversed
by gene retraction.

The first item is entirely for Chinese groups

Clinical studies of irinotecan hydrochloride liposome injection combined with 5-FU/LV second-line treatment of advanced pancreatic cancer with positive results

The affiliated Renji Hospital International Stage showcases the Chinese program

The 2022 European Society for Internal Oncology (ESMO) Annual Meeting, one of the world's top three oncology societies, kicked off on September 9, 2022 in Paris
, France.

Pancreatic ductal adenocarcinoma is one of
the most common tumors of high malignancy.

The HR-IRI-APC study, led by Professor Qin Shukui of the Eastern Theater General Hospital and Professor Wang Liwei of Renji Hospital, is a national multi-center, randomized, double-blind, controlled Phase III clinical study
.

The choice of drugs for the second-line treatment of pancreatic cancer is very limited, domestic drug clinical research is now in a thriving situation, HR070803 as the first Chinese independent research and development of pancreatic cancer second-line treatment to carry out phase III.